EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

NGeneBio Co. Ltd. (354200) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of NGeneBio Co. Ltd. KRW 965, price KRW 1,274, upside -24.3%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

NC Thin data Sep 24, 2026

NGeneBio Co. Ltd.

354200 · KQ

Weak valuationQuality is weak on top of the rich price.

!Fair value 964.93 KRW · Overvalued (−24%)
!Quality 29/100
!Expensive Growth (revenue 5y +53.7 %/yr)
!Loss-making · -22.4% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 1 out of 100
Watch NGeneBio Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

59,826 KRW 1,263 KRW Fair Value 964.93 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,263 KRW – 59,826 KRW · fair‑value band 720.09 KRW – 1,440 KRW · the 1,274 KRW price screens above the 964.93 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow NGeneBio Co. in your weekly email

Every Wednesday you see whether NGeneBio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software.

Show more

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test. The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS. In addition, it offers MTBaccuPanel, a diagnostic panel to test mycobacterium tuberculosis, identification of nontuberculous mycobacteria species, and detection of mutations associated with drug resistance; and NGenePlex nCoV qRT-PCR Kit, a reagent of real-time reverse transcription-polymerase chain reaction assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19. The company was incorporated in 2015 and is headquartered in Seoul, South Korea.

Stock analysis

NGeneBio Co. Ltd. (354200) currently trades at 1,274 KRW, while our model-based Fair Value estimate is 964.93 KRW, implying the stock looks roughly 32.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 720.09 KRW (bear) to 1,440 KRW (bull), the price of 1,274 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

NGeneBio Co. Ltd. reported revenue of 21.2B KRW in FY2025 versus 7.2B KRW in FY2021, a compound +31.2%/yr. Reported net income was −5.5B KRW in FY2025.

Key figures

Market cap 31.9B KRW (≈ $23.4M) · P/S ratio 0.81 · Net margin −26.1% · Return on equity −29.0% · Return on assets (EBIT) −25.4% · Operating margin −13.1% · Revenue (TTM) 31.2B KRW · Revenue growth (YoY) +500%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 81% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −24%, 354200 screens richer than that median.

Fair Value models

Bear 720.09 KRW Fair Value 964.93 KRW Bull 1,440 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,081 KRW 1,449 KRW 2,163 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,081 KRW 1,449 KRW 2,163 KRW 54

Open the full fair value analysis →

Notify me when 354200 reaches fair value

Put 354200 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 29 · Market factors (momentum, volatility) 12

Profitability 4
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 23
Earnings quality: real cash, not paper profit
Fin. Strength 19
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 39
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+273.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−246.2% (2020) → −39.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

354200 screens 32% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare NGeneBio Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −24% · Above median
Profitability
Return on assets −10% · Below median
Net margin (TTM) −22% · Below median
Operating margin (TTM) −13% · Bottom 25%
Growth and dividend
Revenue growth 500% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NGeneBio Co. Ltd. · Fair Value
964.93 KRW −32%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "NGeneBio Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/354200

Frequently asked questions

Is NGeneBio Co. Ltd. (354200) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 964.93 KRW versus a price of 1,274 KRW, about −24% upside (overvalued).
What is the fair value of 354200?
Our model-based fair value for NGeneBio Co. Ltd. is 964.93 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,274 KRW.
What is the quality score of 354200?
NGeneBio Co. Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NGeneBio Co. Ltd. (354200)?
Our model-based price target is the fair value of 964.93 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 720.09 KRW, optimistic scenario 1,440 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NGeneBio Co. Ltd. stock forecast for 2026?
Our models put fair value at 964.93 KRW, about −24% upside versus a price of 1,274 KRW (overvalued). Cautious scenario 720.09 KRW, optimistic scenario 1,440 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NGeneBio Co. Ltd. (354200)?
NGeneBio Co. Ltd. reported trailing-twelve-month revenue of about 31.2B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of NGeneBio Co. Ltd. (354200)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NGeneBio Co. Ltd. it is 964.93 KRW per share (as of Sep 24, 2026), against a price of 1,274 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is NGeneBio Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 354200 trades above its calculated fair value: price 1,274 KRW, fair value 964.93 KRW, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 354200?
No. The price is what the market pays today (1,274 KRW); the fair value is what the company's own numbers justify (964.93 KRW). For NGeneBio Co. Ltd. the two are 309.07 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NGeneBio Co. Ltd. worth?
The market values NGeneBio Co. Ltd. at about 31.9B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,274 KRW; our models calculate a fair value of 964.93 KRW per share.
What do the bullish and bearish scenarios say about 354200?
Our models span a range for NGeneBio Co. Ltd.: cautious scenario 720.09 KRW, base 964.93 KRW, optimistic 1,440 KRW per share (as of Sep 24, 2026, price 1,274 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NGeneBio Co. Ltd. (354200)?
Balance-sheet figures for NGeneBio Co. Ltd. (as of Sep 24, 2026): return on equity −29.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 354200 from its 52-week high?
NGeneBio Co. Ltd. trades at 1,274 KRW, about 81% below its 52-week high of 6,652 KRW and 1% above the low of 1,263 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 964.93 KRW is for.
Which stocks are comparable to NGeneBio Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NGeneBio Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 1,274 KRW, calculated fair value 964.93 KRW (−24%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 354200 calculated?
We run NGeneBio Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 964.93 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. NGeneBio Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NGeneBio Co. Ltd. (354200)?
The closing price on Sep 23, 2026 was 1,274 KRW. Our model-based fair value is 964.93 KRW, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NGeneBio Co. Ltd. right now?
Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (720.09 KRW to 1,440 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NGeneBio Co. Ltd.

How large is the market capitalisation of NGeneBio Co. Ltd. (354200)?
The market capitalisation of NGeneBio Co. Ltd. is 31.9B KRW (≈ $23.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NGeneBio Co. Ltd. (354200)?
The price-to-sales ratio of NGeneBio Co. Ltd. is 0.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of NGeneBio Co. Ltd. (354200)?
The net margin of NGeneBio Co. Ltd. is −26.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NGeneBio Co. Ltd. (354200)?
The return on equity (ROE) of NGeneBio Co. Ltd. is −29.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NGeneBio Co. Ltd. (354200)?
On an EBIT basis the return on assets of NGeneBio Co. Ltd. is −25.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NGeneBio Co. Ltd. (354200)?
The operating margin of NGeneBio Co. Ltd. is −13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NGeneBio Co. Ltd. (354200)?
Revenue at NGeneBio Co. Ltd. is growing +500% versus a year earlier (3y avg +24.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NGeneBio Co. Ltd. (354200) generate?
The free cash flow of NGeneBio Co. Ltd. is −8.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NGeneBio Co. Ltd. (354200) carry?
The net debt of NGeneBio Co. Ltd. is 30.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NGeneBio Co. Ltd. in the live analysis

One click puts NGeneBio Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.